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pN1 but not pN0/N2 predicts survival benefits of prophylactic 
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Background: Prophylactic cranial irradiation has been shown to reduce brain metastases and provide 
survival benefits in small-cell lung cancer (SCLC). However, its role in limited-stage SCLC patients after 
surgery remains unclear. Further, it is unknown whether the effect of prophylactic cranial irradiation is 
generalizable in these patients with different pathological nodal (N0-N2) stages, a state indicating the 
presence of tumor metastases. 
Methods: We combined data from a single medical center and Surveillance, Epidemiology, and End Results 
database. Propensity score matching analyses were performed (1:2) to evaluate the role of prophylactic 
cranial irradiation in SCLC patients after surgery. Cox proportional hazards regression model was used to 
identify predictors of survival. 
Results: 124 (18.7%) out of 664 surgically-treated SCLC patients received prophylactic cranial irradiation 
treatment. Within the entire cohort, multivariate Cox regression analysis identified dataset source, 
age, pathological T and N stages, adjuvant chemotherapy, resection type, and histology as independent 
prognostic factors for overall survival. Prophylactic cranial irradiation appeared to be associated with a better 
overall survival, but the difference is marginally significant (P=0.063). Further, we stratified patients based 
on the pathological N0-N2 stages using propensity score matching analyses, which showed that prophylactic 
cranial irradiation treatment was superior to non-prophylactic cranial irradiation treatment for surgically-
treated SCLC patients with N1 stage only (univariate analysis: P=0.026; multivariate Cox: P=0.004), but not 
N0/N2 stage (univariate analysis: P=0.65 and P=0.28, respectively; multivariate Cox: P=0.99 and P=0.35, 
respectively).
Conclusions: Prophylactic cranial irradiation provides survival benefits for SCLC patients with pN1 after 
surgery but not with pathological N0/N2 stage. Our findings may provide helpful stratifications for clinical 
decision-making of prophylactic cranial irradiation intervention in SCLC patients.
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Introduction
Small-cell lung cancer (SCLC) is a highly aggressive 
neuroendocrine tumor, characterized by a dismal prognosis, 
rapid growth, and early distant metastasis (1,2). One of 
the distinguishing features of SCLC is the tendency to 
metastasize to the brain (3). Approximately 10% of SCLC 
patients have brain metastases (BM) at diagnosis, and this 
percentage expands over time, reaching more than 50% in 
2-year survivors (3). However, only 27% of SCLC patients 
with BM respond to systemic chemotherapy. This resistance 
is mainly attributed to the presence of the blood-brain 
barrier (4,5).
Given the high frequency of BM and propensity for 
micrometastasis with early-stage disease, prophylactic 
cranial irradiation (PCI) has been shown to decrease the 
development of BM and prolong survival in SCLC patients 
(6,7). PCI has ever been recommended as an element 
of standard care for extensive- (ES-SCLC) or limited-
stage SCLC (LS-SCLC) patients with complete/partial 
remission after first-line treatment (8). However, a recent 
randomized clinical trial challenged the role of PCI in ES-
SCLC patients with any response to initial chemotherapy, 
in that PCI significantly reduces the incidence of BM (48% 
vs. 69%; P<0.0001), but does not improve overall survival 
(P=0.094), compared with observation group (9). Further, 
recent evidence showed no significant survival benefit from 
PCI in ES-/LS-SCLC patients without BM confirmed 
by brain magnetic resonance imaging (MRI) after initial 
treatment (9-11). Thus, how to stratify SCLC patients for 
precise PCI interventions remains a question.
Additionally, increasing evidence suggests a critical role 
of surgery in patients with resectable LS-SCLC tumors, 
along with adjuvant chemotherapy, significantly prolong 
survival (3,12-15). Accordingly, the National Comprehensive 
Cancer Network guideline has recommended surgery for 
LS-SCLC patients at an early-stage without lymph node 
metastasis (T1–2, N0). Besides, some recent studies have 
demonstrated that PCI can decrease the incidence of BM and 
improve the prognosis of patients with resectable LS-SCLC 
after surgery (14,16-18); however, the target populations 
that can considerably benefit from PCI is not yet specified. 
Of note, PCI is known to be related to neurotoxicity, which 
needs to be critically considered before clinical employment. 
Since there is little information on PCI after resection of 
early SCLC (19), whether to perform PCI for all SCLC 
patients after surgery is of high importance that needs further 
research. Additionally, few studies have investigated the 
relationship between PCI treatment effect and different 
pathological nodal (pN0-N2) status at surgery, a critical 
factor indicating the occurrence of tumor metastasis and 
influencing the prognosis of cancer patients. 
In this study, we sought to determine the effect of PCI 
on LS-SCLC patients after surgery, and which subsets, 
according to pN0-N2 status, can benefit from PCI. For this 
purpose, we combined data from a single medical center 
and Surveillance, Epidemiology, and End Results (SEER) 
program, given the sparsity of surgically-resected LS-SCLC 
cases and a generally low incidence of PCI interventions for 
this population. 
We present the following article in accordance with the 




This study was approved by the Institutional Review Board 
of Shanghai Chest Hospital (SCH) (Shanghai, China). 
Clinical data of SCLC (between 2006 and 2014), including 
age at diagnosis, sex, type of resection (sublobar resection/
lobectomy), histology subtype [pure/combined SCLC 
(combined non-SCLC components)], tumor size, the extent 
of lymph node involvement, adjuvant thoracic radiotherapy 
and chemotherapy. Tumors were staged based on the eighth 
tumor node metastasis classification. To reduce the number 
of prognosis-influencing factors, we targeted the group 
of surgically-treated patients with complete resections. 
The inclusion criteria were as follows: (I) pathologically-
confirmed SCLC; (II) surgery with complete resection as 
initial treatment for primary SCLC tumor. The exclusion 
criteria were: (I) patients who had positive surgical margins 
(including microscopically-positive and macroscopically-
positive); (II) patients without survival and therapy 
(particularly PCI treatment) details; (III) patients with 
N3/stage IV disease; (IV) postoperative survival time less 
than three months; (V) SCLC was not identified as the 
first primary cancer (to exclude the cases whose survival 
might be significantly affected by the prior cancer). Overall 
survival (OS) was defined as the time from diagnosis until 
death from any cause or last follow-up visit. The study was 
conducted in accordance with the Declaration of Helsinki (as 
revised in 2013). The participants gave informed consent 
before taking part. The study was approved by ethics board 
of Shanghai Chest Hospital (FS202007).
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In this study, we used the SEER public database from 
1975–2016 datasets (November 2018 submission) for 
this study. We requested the data from the public SEER 
database portal (www.seer.cancer.gov), then we received 
the approval to get access to the database. Histology and 
site of the disease are coded in SEER according to the 
International Classification of Diseases (ICD) for Oncology, 
Edition 3 (ICD-O-3). Data of patients with SCLC (ICD-
0-3 histology code 804.1) of the lung (ICD-0-3 site code 
c34.0-c34.9) were extracted. Then the data of patients 
undergoing complete resection were filtered and analyzed. 
We included cases only diagnosed between 1988 and 
1997 because the delivery of whole-brain radiotherapy 
was not specifically recorded during other years (20,21). 
Furthermore, we excluded SCLC patients with N3/stage 
IV or unknown T/N stage disease, those not diagnosed 
with SCLC as the first primary cancer, or survived less than 
three months postoperatively.
A total of 664 SCLC patients, including 298 from SCH 
and 366 from the SEER database, were included for analysis.
Study design
Initially, we investigated the effect of PCI treatment based 
on the entire patient cohort, then further analysis according 
to the pN0-N2 status of surgically-resected SCLC tumors 
was performed. The workflow was summarized in Figure 1.
Statistical analysis
Normally distributed continuous variables were presented 
as the mean ± SD, otherwise presented as the median and 
range. Categorical variables were shown as numbers and 
percentages. Fisher’s exact test and a chi-square test were 
used to compare categorical variables, while a t-test was 
used to compare continuous variables. Survival curves 
were estimated using the Kaplan-Meier method and 
compared using the log-rank test. The propensity score 
matching (PSM) analyses (1:1 or 1:2; by nearest-neighbor 
matching) was performed to control the differences in 
baseline characteristics between two groups (PCI vs. non-
PCI treatment) (22), such as the source of datasets (SHC 
vs. SEER), age, sex, histology subtype, type of resection, 
adjuvant thoracic radiotherapy and chemotherapy, and 
pathological characteristics. In the case of good matching 
(1:1 and 1:2), 1:2 matching was preferred to achieve 
sufficient statistical power, given the small sample size in 
our study. Then, univariate Kaplan-Meier and multivariate 
Small cell lung cancer patients (SCLC) undergoing surgery
Datasets 
• Single medical center (n=438)
• SEER database (n=1391)
Excluded (SEER database)
• No treatment and
• survival infomation (n=134)
• Unknown T stage (n=42)
• SCLC not as first tumor (n=68)
• Stage IIIB/IV or unknown N/M stage (n=745)
• Overall survival <3 months (n=36)
SCLC with complete resection
• Single medical center (n=298)
• SEER database (n=366)
PCI vs. Non-PCI treatment
1. Pooled multivariate Cox regression analysis
• Identify independent prognostic factors
2. Stratified analyses (propensity score matching)




Excluded (single medical center)
• No treatment and
• survival infomation (n=61)
• Surgical biopsies or uncertain (n=15)
• Positive surgical margin (n=17)
• SCLC not as first tumor (n=2)
• Stage IIIB/IV (n=26)
• Overall survival <3 months (n=19)
Figure 1 The workflow of this study.
Yang et al. Stratified management of PCI for SCLC
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2021;9(7):562 | http://dx.doi.org/10.21037/atm-20-6984
Page 4 of 13
Cox regression analyses were performed on the subgroup 
of matched patients. All tests were two-sided, and a P value 
<0.05 was considered to indicate statistical significance. 
Statistical analyses were performed using R software (version 
3.6.3). PSM and survival analyses were performed using R 
packages ‘MatchIt’ (for PSM), ‘survival’ and ‘survminer’ (for 
survival), respectively.
Results
Patient characteristics and prognostic factors
The clinical characteristics of all SCLC patients included 
in this study were shown in Table 1. Of the 664 surgically-
treated SCLC patients included, 124 (18.7%) received 
PCI. Multivariate Cox regression analysis (Figure 2A) 
identified SHC-based dataset [hazards ratio (HR) = 1.35, 
95% confidence interval (CI): 1.04–1.75], age (61–70 years, 
HR =1.46, 95% CI: 1.03–2.06; 71–80 years: HR =2.19, 
95% CI: 1.51–3.18), high pT (T2: HR =1.25, 95% CI: 
1.03–1.53; T3: HR =2.13, 95% CI: 1.49–3.05; T4: HR 
=3.65, 95% CI: 2.46–5.41), high pN (pN1: HR =1.98, 
95% CI: 1.55–2.52; pN2: HR =2.36, 95% CI: 1.86–2.99), 
adjuvant chemotherapy (HR =0.62, 95% CI: 0.51–0.77), 
type of resection (sublobar resection: HR =1.36, 95% CI: 
1.05–1.77), and histology (pure SCLC: HR =1.40, 95% CI: 






Sex (%) Female 194 (35.9) 18 (14.5) <0.001
Male 346 (64.1) 106 (85.5)
Age [mean (SD)] 63.53 (9.06) 59.47 (8.54) <0.001
Surgery (%) Lobectomy 407 (75.4) 97 (78.2) 0.002
Pneumonectomy 51 (9.4) 20 (16.1)
Sublobar 82 (15.2) 7 (5.6)
Histology (%) Combined SCLC 99 (18.3) 31 (25.0) 0.103
Pure SCLC 441 (81.7) 93 (75.0)
pT stage (%) T1 226 (41.9) 42 (33.9) 0.246
T2 242 (44.8) 68 (54.8)
T3 41 (7.6) 9 (7.3)
T4 31 (5.7) 5 (4.0)
pN stage (%) N0 252 (46.7) 37 (29.8) 0.002
N1 122 (22.6) 39 (31.5)
N2 166 (30.7) 48 (38.7)
Database (%) SEER 342 (63.3) 24 (19.4) <0.001
SH 198 (36.7) 100 (80.6)
Thoracic RT (%) No 328 (60.7) 33 (26.6) <0.001
Yes 212 (39.3) 91 (73.4)
Chemotherapy (%) No 168 (31.1) 13 (10.5) <0.001
  Yes 372 (68.9) 111 (89.5)  
pT, pathological T; pN, pathological N; RT, radiotherapy; SHC, Shanghai Chest Hospital; Combined SCLC means the presence of  
non-SCLC components (>10%) within tumor.
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Figure 2 Prognostic factors of small-cell lung cancer (SCLC) patients after surgery. (A) Forest plot shows the independently prognosis-
influencing factors identified by multivariate Cox regression analysis; (B) Covariates-adjusted Kaplan-Meier analyses of the indicated factors 
in the entire SCLC patient cohort.
A
B
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1.07–1.83) as independent factors for OS. PCI appeared to 
be associated with a better OS, although the difference was 
not significant (HR =0.76, 95% CI: 0.58–1.02, P=0.063). 
Covariates-adjusted Kaplan-Meier analyses of these 
prognosis-influencing factors were shown in Figure 2B.
The association between PCI effect and pN0-N2 stage
Tumor-positive lymph nodes are closely associated with 
distant metastasis and poor prognosis. Next, we sought to 
investigate whether the extent of lymph node involvement 
relates to the PCI effect. Thus, we performed PSM analyses 
(1:2) to evaluate the role of PCI in SCLC patients based on 
pN0-N2 stratifications. 
pN0
After matching the baseline characteristics (Figure 3A), 
PSM analyses showed that there was no significant survival 
difference (P=0.65) between PCI and non-PCI group at the 
pN0 stage (Figure 3B). Further, multivariate Cox regression 
analysis identified age (71–80 years: HR =4.46, 95% CI: 
1.45–13.7) and pT (T3: HR =3.20, 95% CI: 1.30–7.9), but 
not PCI (HR =1.00, 95% CI: 0.57–1.7), as significantly 
independent factors for OS (Figure 3C). The co-variates-
adjusted survival curve of pN0-stage SCLC patients with 
and without PCI treatment was shown in Figure S1A.
pN1
Concerning patients with the pN1 stage, PSM analysis 
(Figure 4A) showed that the PCI group had significantly 
better OS than the non-PCI group (P=0.026; Figure 4B). 
Also, multivariate Cox regression analysis identified age 
(51–60 years: HR =2.40, 95% CI: 1.03–5.61) and pT (T4: 
HR =4.52, 95% CI: 1.54–13.21), as well PCI as (HR =0.43, 
95% CI: 0.24–0.76), as significantly independent factors for 
OS (Figure 4C). The co-variates-adjusted survival curve of 
pN1-stage SCLC patients with and without PCI treatment 
was shown in Figure S1B.
pN2
Within the pN2-stage, we did not observe the superiority of 
PCI treatment after performing PSM (Figure 5A), as there was 
no survival advantage in the PCI group (P=0.28; Figure 5B). 
Additionally, multivariate Cox regression analysis only 
identified pT (T2: HR =2.80, 95% CI: 1.542–5.08; T3: 
HR =4.82, 95% CI: 1.950–11.93; T4: HR =5.83, 95% CI: 
1.783–15.76) and adjuvant chemotherapy (HR =0.16, 95% 
CI: 0.073–0.33), rather than PCI (HR =0.80, 95% CI: 
0.498–1.28), as significantly independent factors for OS 
(Figure 5C). The co-variates-adjusted survival curve of pN2-
stage SCLC patients with and without PCI treatment was 
shown in Figure S1C.
Additionally, given that the above evidence showed pN1 
as a potential biomarker predicting the survival benefit 
from the PCI treatment, we then separately analyzed the 
two cohorts by focusing on the pN1 stage. Cox multivariate 
analysis demonstrated that pN1 stage significantly predicts 
the OS of resected SCLC from our single institutional 
dataset (Figure S2A) but not SEER (Figure S2B). The 
difference can be explained by the fact that only a small 
proportion of resected SCLC cases (n=5) undergoing 
PCI treatment in the SEER database. In contrast, in our 
institutional dataset, 34 of 78 resected SCLC cases received 
PCI treatment after surgery.
Discussion
SCLC is a highly aggressive malignancy with a tendency 
for early dissemination (1). Despite the initial sensitivity to 
chemo-radiotherapy, treatment usually fails because of BM (4). 
The keystone in treating LS-SCLC patients depends on 
the use of chemotherapy (etoposide and cisplatin) and chest 
radiotherapy. This regimen is followed by PCI when the 
patient has good performance status (8). The importance of 
PCI in controlling BM was previously recognized (6,7), but 
challenged recently (9), leading to its controversy. 
The role of PCI in early-stage SCLC after surgery
Recently, increasing evidence has shown the critical role of 
surgery in SCLC patients, even at an advanced p-IIIA-N2 
stage (12,14,15,23). Due to the paucity of cases undergoing 
surgery, the effect of PCI on SCLC patients who underwent 
surgical resection for the primary tumor remains unclear. 
We and other groups have shown that PCI could improve 
OS and decrease BM in SCLC patients with p-II/III stage, 
but not p-I stage, which is likely due to the low incidence of 
BM in patients with p-I stage (16-18,24). Specifically, recent 
data from our center showed that of the 146 surgically 
resected SCLC patients without lymph node involvement 
(pN0), only 11.6% (17/146) of patients developed BM, 
and PCI does not reduce the risk of cerebral recurrence of 
resected pT1–2N0M0 SCLC (17). These data suggest that 
PCI may play a limited role in the very early-stage SCLC.
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Figure 3 PCI treatment for pN0 stage small-cell lung cancer (SCLC) patients after surgery. (A) Distribution of propensity matching scores 
(PSM) between pN0 stage SCLC patients with and without PCI (prophylactic cranial irradiation) treatment; (B) PSM-based Kaplan-Meier 
analyses of SCLC patients with and without PCI; (C) Forest plot shows the independently prognosis-influencing factors identified by 
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Figure 4 PCI treatment for pN1 stage small-cell lung cancer (SCLC) patients after surgery. (A) Distribution of propensity matching scores 
(PSM) between pN1 stage SCLC patients with and without PCI (prophylactic cranial irradiation) treatment; (B) PSM-based Kaplan-Meier 
analyses of SCLC patients with and without PCI; (C) Forest plot shows the independently prognosis-influencing factors identified by 
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Figure 5 PCI treatment for pN2 stage small-cell lung cancer (SCLC) patients after surgery. (A) Distribution of propensity matching scores 
(PSM) between pN2 stage SCLC patients with and without PCI (prophylactic cranial irradiation) treatment; (B) PSM-based Kaplan-Meier 
analyses of SCLC patients with and without PCI; (C) Forest plot shows the independently prognosis-influencing factors identified by 
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The role of PCI in advanced-stage SCLC with lymph node 
metastasis after surgery
Identifying subsets of SCLC patients who can benefit 
from PCI intervention is an urgent need and remains a 
clinical challenge. Here, we investigated the role of PCI 
in surgically-treated SCLC, stratifying patients based on 
the extent of lymph node involvement (pN0-N2), given 
that lymph node involvement is tightly related to tumor 
metastasis. The stratifications were biologically and 
clinically relevant, and could also reduce the dimension of 
confounding factors. Supporting this notion, a recent study 
by Resio et al. analyzed data of 859 SCLC patients who 
underwent complete resection as the primary treatment (18). 
Subset analyses showed that a survival benefit from PCI 
was evident only in patients with positive lymph node 
involvement (18). However, it is unclear whether patients 
with different extent of lymph node involvement (e.g., 
pN1/N2) have differential survival benefits after PCI 
treatment (18). In our study, we found that PCI treatment 
could provide a survival advantage in patients at pN1 but 
not pN0/N2 stage. This survival benefit was evident from 
PSM-based univariate and multivariate Cox analyses. In 
general, pN0 belongs to the p-I stage that associates with 
a low incidence of BM (16-18,24), which could explain 
the unbeneficial role of PCI treatment in this subgroup. 
Additionally, we observed that PCI was not superior to the 
non-PCI group in patients with pN2, which predominantly 
belongs to p-stage III. This observation appeared to be at 
odds with previous studies demonstrating survival benefits 
from PCI treatment in p-stage II-III SCLC patients (16,18), 
which might be due to the higher heterogeneity of patients 
within p-III classification than that of pN2. Also, previous 
study cohorts were not well-matched between the PCI and 
non-PCI treatment group, given that PSM analyses used in 
this study could reduce the bias by confounding factors (25). 
Further, patients with a more advanced pN2-stage might 
die of multiple dysfunctions of other metastasized organs 
other than the BM alone, in that SCLC tumors at distinct 
stages have varying metastatic patterns, leading to different 
prognosis (26,27). Milovanovic et al. demonstrated that 
SCLC metastases were most commonly observed in the 
liver (more than 35%), followed by adrenal glands (20%), 
bone (17.6%), brain (13.7%), and myocardium (13.7%) (27). 
Of note, evidence from the same study showed that in 
SCLC patients who survived less than one year after 
diagnosis, liver metastases were the most common (33%), 
followed by intestinal metastases (22%). Further studies are 
required to investigate whether the extent of lymph node 
involvement predicts different patterns of distant metastasis 
and organ-specific death in SCLC patients after surgery. 
Notably, many research groups, including ours, showed 
some inconsistencies between clinical and pathological 
stages (12,28,29), which might be due to that SCLC 
is highly aggressive with a high propensity for occult 
metastasis. Final histopathological analysis upstaged about 
20% of SCLC patients with c-stage I/II to p-III (12,29), 
thus, indicating that p- rather than c-stage is a more reliable 
marker to guide PCI treatment based on our findings. 
Neurotoxicity following PCI in SCLC
However, the potential advantages of PCI should be 
balanced with possible side-effects. One of the side-effects 
related to this treatment modality is neurotoxicity. Briefly, 
all patients have the chance to develop acute toxic effects 
of PCI, like alopecia, headache, ear infection, fatigue, and 
nausea (30). Previous trials found that PCI is associated 
with a decrease in self-reported cognitive functioning 
and (Hopkins verbal learning test)-Recall and delayed 
recall at 6 and 12 months, especially in those above ages 
of 60 (4). Further, the optimal dose of PCI for LS-SCLC 
patients needs to be considered, as a higher dose of PCI is 
associated with more neurotoxic effects. A previous clinical 
trial showed that compared to the standard-dose PCI in 
patients with LS-SCLC, a higher-dose PCI is not associated 
with a significant reduction in the total incidence of brain 
metastases, but with a considerable increase in mortality (31). 
Thus, before applying PCI, we should weigh the balance 
between the benefits and risks of this treatment modality.
Therefore, it is critical to determine the subgroups that 
will not benefit from the treatment, thereby avoiding PCI-
treatment-related neurocognitive impairment. Although the 
neurotoxic data of SCLC patients after PCI treatment in 
the current study were not available, we identified that only 
a subgroup of SCLC patients (p-N1 stage) after complete 
resection could benefit from PCI treatment, which might 
provide new insights into SCLC patient selection for PCI 
treatment. 
Limitations
The major limitation of this study is the retrospective 
nature. Particularly, the combined datasets are from 
different periods, which, however, might not be critical, 
given that the treatment strategies for SCLC have not 
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changed significantly in the past three decades, and that 
we incorporated dataset source as a confounding factor 
for adjustment in the multivariate Cox and PSM analyses. 
Furthermore, some potentially prognosis-influencing 
factors, such as smoking history (in SHC dataset, ~90% 
of SCLC patients have smoking history), the performance 
status of patients, and the regimens and cycles of 
chemotherapy, are lacking in the SEER databases. Besides, 
baseline MRI scans are not available, as recent studies 
demonstrated no significant survival benefit from PCI in 
SCLC patients without BM confirmed by brain MRI after 
initial treatment (9-11).
Conclusions
In summary, our study showed PCI provided survival 
benefits for stage N1 but not N0/N2 SCLC patients after 
surgery. The results of this study suggest that the use of 
the extent of lymph node involvement may be helpful for 
clinical decision-making of PCI intervention in SCLC 
patients after surgery. More studies are needed not only to 
investigate the effect of PCI treatment in SCLC patients 
after complete resection but also whether the extent of 
lymph node involvement predicts different patterns of 
metastasis. Since only a minority of SCLC patients undergo 
surgery, a well-designed, multi-center, prospective study is 
required.
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Figure S1 Survival analysis of SCLC patients with and without PCI treatment, stratified based on pN0-pN2 status after surgery. (A,B,C) 
Covariates-adjusted Kaplan-Meier analyses of SCLC patients with and without PCI treatment, stratified based on pN0 (A), pN1 (B), pN2 (C) 
after propensity matching scores (PSM).
Figure S2 Separately survival analysis of SCLC patients with pN1 status after surgery. (A,B) Forest plot shows the independently prognosis-
influencing factors identified by multivariate Cox regression analysis SCLC patients with pN1, based on single institutional (A) and SEER 
datasets (B), respectively. 
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